Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
After 56 days, discard the pen even if medication remains inside
In the most recent trial, some participants taking retatrutide lost up to 24.2% of their total body weight in just 48 weeksmore weight, and in a shorter time, than was seen with tirzepatide
Several large-scale cardiovascular outcome trials (including LEADER, SUSTAIN-6, and REWIND) have shown that certain GLP-1 receptor agonists liraglutide, semaglutide, and dulaglutide reduce the risk of major adverse cardiovascular events such as heart attack, stroke, and cardiovascular death in people with established cardiovascular disease or multiple cardiovascular risk factors
As far as the researchers know, this is the first piece of evidence ever to suggest that semaglutide could raise the risk of NAION
Company announcement: Novo Nordisk A/S: Wegovy pill approved in the US as first oral GLP-1 for weight management
Recent findings GLP-1 RA use is increasing in popularity in the USA, with expanding applications for gynecology
